前沿速览034期| CAR-T治B淋 前沿览新知
01
诱导多能干细胞来源的CD19靶向嵌合抗原受体自然杀伤细胞在B细胞淋巴瘤中的应用：一项I期、首次人体试验
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
第一作者：Ghobadi A
Lancet (IF=98.4). 2025 Jan 11;405(10473):127-136.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(24)02462-0
02
DESCAR-T登记研究中CAR-T细胞治疗后的T细胞恶性肿瘤发生情况
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
第一作者：Dulery R
Nat Med (IF=58.7). 2025 Jan 8.
全文网址：https://www.nature.com/articles/s41591-024-03458-w
03
初次抗CD19 CAR-T细胞治疗对复发/难治性大B细胞淋巴瘤患者后续抗CD22 CAR-T细胞制备及临床结局的影响
Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL
第一作者：Su YJ
Cancer Discov (IF=30.6). 2025 Jan 7.
全文网址：https://aacrjournals.org/cancerdiscovery/article-abstract/doi/10.1158/2159-8290.CD-24-1071/750834/Effects-of-an-initial-anti-CD19-CAR-T-cell-therapy?redirectedFrom=fulltext
04
Prizloncabtagene autoleucel (CD19/CD20 CAR-T细胞疗法) 治疗复发/难治性B细胞非霍奇金淋巴瘤的I期试验
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
第一作者：Yu W
Blood (IF=21.1). 2025 Jan 15:blood.2024026401.
全文网址：https://ashpublications.org/blood/article/doi/10.1182/blood.2024026401/535112/A-phase-1-trial-of-prizloncabtagene-autoleucel-a
05
CD19 CAR-T细胞治疗复发/难治性B细胞淋巴瘤后免疫重建对预后的意义
Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma
第一作者：Stock S
Hemasphere (IF=11.9). 2025 Jan 13;9(1):e70062.
全文网址：https://onlinelibrary.wiley.com/doi/full/10.1002/HEM3.70062
06
PARP抑制剂奥拉帕利可增强大剂量化疗和自体造血干细胞移植治疗难治性淋巴瘤的效果
Enhancement Of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma
第一作者：Nieto Y
Clin Cancer Res (IF=10.4). 2025 Jan 13.
全文网址：https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-24-3544/751075/Enhancement-Of-High-Dose-Chemotherapy-and?redirectedFrom=fulltext
07
治疗前肺功能检测在CD19 CAR-T细胞治疗B细胞淋巴瘤中的应用价值有限
Pre-treatment Pulmonary Function Testing Has Limited Utility In B-cell Lymphoma Treated with CD19 CAR T-cells
第一作者：Sdayoor I
Blood Adv (IF=7.4). 2025 Jan 7:bloodadvances.2024014488.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024014488/534948/Pre-treatment-Pulmonary-Function-Testing-Has
08
CAR-T疗法在B细胞血液系统恶性肿瘤之外的应用
CAR-T Therapy Beyond B-Cell Hematological Malignancies
第一作者：Canichella M
Cells (IF=5.1). 2025 Jan 3;14(1):41.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11719893/
09
抑制Cbl-b可提高抗CD19 CAR - T细胞的制备效率和抗肿瘤效果
Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells
第一作者：Wang H
Int Immunopharmacol (IF=4.8). 2025 Jan 2;147:113971.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S1567-5769(24)02493-7
10
输注后CAR-T细胞扩增减少与接受两种及以上治疗的弥漫性大B细胞淋巴瘤患者的生存不佳相关
Reduced CAR T expansion post infusion is associated with poor survival in patients with large B cell lymphoma after two or more therapies
第一作者：Abadir E
Transplant Cell Ther (IF=3.6). 2025 Jan 6:S2666-6367(25)00002-8.
全文网址：https://www.sciencedirect.com/science/article/abs/pii/S2666636725000028?via%3Dihub
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.1-15 valid until 2027.1
供稿与审核：临床开发与医学部